<DOC>
	<DOCNO>NCT00296608</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , fluorouracil leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know whether radiation therapy effective without chemotherapy give surgery rectal cancer . PURPOSE : This randomized phase III trial study radiation therapy give together fluorouracil leucovorin see well work compare give radiation therapy alone surgery treat patient stage II stage III rectal cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy Before Surgery Treating Patients With Stage II Stage III Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare recurrence-free overall survival patient resectable stage II III adenocarcinoma rectum treat neoadjuvant radiotherapy without concurrent chemotherapy comprise fluorouracil leucovorin calcium follow surgery adjuvant fluorouracil leucovorin calcium . OUTLINE : This randomize , control , multicenter study . Patients stratify accord participate center , gender , location tumor relative anal margin ( 0-5 cm v &gt; 5 cm ) , tumor stage ( T3 v T4 ) . Patients randomize 1 2 treatment arm . - Neoadjuvant therapy : Patients randomize 1 2 neoadjuvant therapy arm . - Arm I : Patients receive leucovorin calcium IV fluorouracil IV 15 minute day 1-5 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients also undergo concurrent radiotherapy 5 day week 5 week . - Arm II : Patients undergo radiotherapy arm I . - Surgery : In arm , patient undergo surgical resection within 3-10 week complete neoadjuvant therapy . - Adjuvant therapy : Within 3-10 week surgery , patient receive adjuvant chemotherapy comprise leucovorin calcium IV fluorouracil IV 15 minute day 1-5 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month least 5 year . PROJECTED ACCRUAL : A total 762 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum meet 1 follow stage criterion : Stage T3 , N02 , M0 disease meet 1 follow criterion : Invasive disease entire circumference ( circular tumor ) Tumor fix laterally posteriorly pelvic structure Tumor adherent prostate and/or seminal vesicle Tumor infiltration vaginalrectal septum Tumor classify uT3 rectal endoscopy Stage T4 , N02 , M0 disease meet 1 follow criterion : Clinical radiologic evidence pelvic organ extension ( vagina , prostate , seminal vesicle , bladder ) Tumor extension anal canal sphincter Tumor classify uT4 rectal endoscopy Tumor accessible digital rectal exam Resectable disease No distant metastases PATIENT CHARACTERISTICS : WHO performance status 01 Creatinine &lt; 1.36 mg/dL Granulocyte count &gt; 2,000/mm^3 Platelet count &gt; 130,000/mm^3 No progressive ischemic cardiomyopathy No acute chronic obstruction unless treat diversion colostomy No chronic inflammation ileum and/or colon No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , surgery cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>